# EDGAR Filing Document

**Accession Number:** 0001763329
**File Stem:** 0001096906-25-001064
**Filing Date:** 2025-6
**Character Count:** 3505
**Document Hash:** 6ac9df5b70eed92c36aff46096261edd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001096906-25-001064.hdr.sgml**: 20250903

**ACCESSION NUMBER**: 0001096906-25-001064

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20250627

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AIBOTICS, INC.
- **CENTRAL INDEX KEY:** 0001763329
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870645794
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 480 22ND STREET
- **CITY:** HEYBURN
- **STATE:** ID
- **ZIP:** 83336
- **BUSINESS PHONE:** 208-677-2020

**MAIL ADDRESS:**
- **STREET 1:** 480 22ND STREET
- **CITY:** HEYBURN
- **STATE:** ID
- **ZIP:** 83336

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Mycotopia Therapies, Inc.
- **DATE OF NAME CHANGE:** 20210519

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 20/20 Global, Inc.
- **DATE OF NAME CHANGE:** 20190102

![Picture 1](tpiacorresp_1.jpg)

June 27, 2025

US Securities and Exchange Commission

Attn: Joe McCann

Division of Corporation Finance

Office of Life Sciences

Washington, D.C. 20549

**Re:** **Aibotics, Inc.** 

**Offering Statement on Form 1-A Filed May 7, 2025**

**File No. 024-12597**

Dear Mr. McCann:

We hereby withdraw our previous request for qualification of the above referenced Offering Statement and replace it with the following. Pursuant to Rule 252(e) promulgated under the Securities Act of 1933, as amended (the "Act"), Aibotics Inc. (the "Company") hereby requests that the Securities and Exchange Commission (the "Commission") issue a qualification order for the above referenced Offering Statement on Form 1A, so that it may be qualified by 4:00 pm., Eastern Time on Tuesday, July 1, 2025, or as soon thereafter as is practicable.

We understand that the Commission has completed its review and has no further comments.

The Company is aware of its responsibilities under the Act, as they relate to this offering of securities. As requested, the Company further acknowledges that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Should the Commission or the staff, acting pursuant to delegated authority, qualify the filing, it does not foreclose the Commission from taking any action with respect to the filing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·The action of the Commission or the staff, acting pursuant to delegated authority, in qualifying the filing, does not relieve the Company from its responsibility for the adequacy and accuracy of the disclosures in the filing; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·The Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

The Company acknowledges that the Company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

If you have any questions, please contact our counsel, Jonathan Leinwand (954) 903-7856.

Thank you in advance for your assistance.

Very Truly Yours,

AIBOTICS INC.

By:/s/ Ben Kaplan

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ben Kaplan, CEO

------

![Picture 1](tpiacorresp_2.jpg)